PTC Therapeutics (PTCT) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

PTC Therapeutics Revenue Highlights

Latest Revenue (Y)

$806.78M

Latest Revenue (Q)

$211.01M

Main Segment (Y)

Product

Main Geography (Y)

United States

PTC Therapeutics Revenue by Period

PTC Therapeutics Revenue by Year

Date	Revenue	Change
2024-12-31	$806.78M	-13.97%
2023-12-31	$937.82M	34.20%
2022-12-31	$698.80M	29.75%
2021-12-31	$538.59M	41.45%
2020-12-31	$380.77M	24.04%
2019-12-31	$306.98M	15.96%
2018-12-31	$264.73M	36.19%
2017-12-31	$194.39M	135.04%
2016-12-31	$82.70M	124.95%
2015-12-31	$36.77M	60.11%
2014-12-31	$22.96M	-26.70%
2013-12-31	$31.33M	8.85%
2012-12-31	$28.78M	-70.92%
2011-12-31	$98.96M	-

PTC Therapeutics generated $806.78M in revenue during NA 2024, up -13.97% compared to the previous quarter, and up 262.81% compared to the same period a year ago.

PTC Therapeutics Revenue by Quarter

Date	Revenue	Change
2025-09-30	$211.01M	17.96%
2025-06-30	$178.88M	-84.79%
2025-03-31	$1.18B	451.71%
2024-12-31	$213.17M	8.33%
2024-09-30	$196.79M	5.40%
2024-06-30	$186.70M	-11.14%
2024-03-31	$210.12M	-31.57%
2023-12-31	$307.06M	56.20%
2023-09-30	$196.58M	-8.06%
2023-06-30	$213.81M	-2.98%
2023-03-31	$220.38M	31.64%
2022-12-31	$167.41M	-22.90%
2022-09-30	$217.13M	31.17%
2022-06-30	$165.53M	11.29%
2022-03-31	$148.74M	-9.98%
2021-12-31	$165.23M	19.09%
2021-09-30	$138.74M	18.91%
2021-06-30	$116.68M	-1.07%
2021-03-31	$117.94M	-0.78%
2020-12-31	$118.86M	0.39%
2020-09-30	$118.40M	57.37%
2020-06-30	$75.24M	10.23%
2020-03-31	$68.26M	-29.24%
2019-12-31	$96.46M	35.07%
2019-09-30	$71.42M	-16.49%
2019-06-30	$85.52M	59.61%
2019-03-31	$53.58M	-37.94%
2018-12-31	$86.34M	61.11%
2018-09-30	$53.59M	-22.04%
2018-06-30	$68.74M	22.62%
2018-03-31	$56.06M	-28.15%
2017-12-31	$78.03M	86.44%
2017-09-30	$41.85M	-12.74%
2017-06-30	$47.96M	80.67%
2017-03-31	$26.55M	5.38%
2016-12-31	$25.19M	9.59%
2016-09-30	$22.99M	47.04%
2016-06-30	$15.63M	-17.26%
2016-03-31	$18.89M	24.17%
2015-12-31	$15.22M	55.69%
2015-09-30	$9.77M	53.49%
2015-06-30	$6.37M	17.77%
2015-03-31	$5.41M	-53.40%
2014-12-31	$11.60M	1355.71%
2014-09-30	$797.00K	-43.79%
2014-06-30	$1.42M	-84.50%
2014-03-31	$9.15M	132.70%
2013-12-31	$3.93M	-74.57%
2013-09-30	$15.46M	163.39%
2013-06-30	$5.87M	-3.37%
2013-03-31	$6.07M	2.60%
2012-12-31	$5.92M	-2.06%
2012-09-30	$6.04M	-0.36%
2012-06-30	$6.06M	-43.60%
2012-03-31	$10.75M	-

PTC Therapeutics generated $211.01M in revenue during Q3 2025, up 17.96% compared to the previous quarter, and up 113.02% compared to the same period a year ago.

PTC Therapeutics Revenue Breakdown

PTC Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 19	Dec 18
Collaboration Revenue	$304.00K	$100.03M	-	-
Product	$600.95M	$291.31M	-	-
Royalty	$203.86M	-	-	-
Manufacturing	$1.66M	$7.69M	-	-
Grant And Collaboration	-	-	$15.67M	-
Early Stage Collaborations	-	-	-	$252.00M
Licensing And Collaboration Agreement	-	-	-	$200.00K
Emflaza	-	-	-	$92.00M
Grant	-	-	-	-
Translarna	-	-	-	$171.00M

PTC Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (74.49%), Royalty (25.27%), Manufacturing (0.21%), and Collaboration Revenue (0.04%).

Quarterly Revenue by Product

Product/Service	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Dec 18
Royalty	$70.79M	$57.60M	$36.44M	$142.50M	$61.37M	$4.09M	$696.00K	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration and License Revenue	$9.26M	$2.94M	$986.23M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product	$130.96M	$118.33M	$153.43M	$465.53M	$135.42M	$103.11M	$91.28M	$107.26M	$82.71M	$75.24M	$68.20M	$81.41M	$71.37M	$85.48M	-	-	-	-	-	-
Manufacturing	-	-	-	-	$800.00K	$1.36M	$3.34M	$2.36M	$1.99M	-	-	-	-	-	-	-	-	-	-	-
Net product revenue	-	-	-	-	-	$177.60M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant And Collaboration	-	-	-	-	-	-	-	-	-	-	-	$7.52M	$35.00M	-	$63.00K	$15.05M	$47.00K	$46.00K	-	-
Licensing And Collaboration Agreement	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$100.00K	$87.50M
Early Stage Collaborations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$252.00M	-

PTC Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Product (62.06%), Royalty (33.55%), and Collaboration and License Revenue (4.39%).

PTC Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Non-US	$393.80M	$406.16M	$288.60M	$236.00M	-
United States	$413.04M	$531.66M	$218.30M	$187.30M	-
UNITED STATES	$413.04M	-	-	-	-
Non Us	-	-	-	-	$194.40M
U	-	-	-	-	$139.00M

PTC Therapeutics's latest annual revenue breakdown by geography, as of Dec 24: United States (33.86%), UNITED STATES (33.86%), and Non-US (32.28%).

Quarterly Revenue by Country

Country	Sep 25	Jun 25	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
UNITED STATES	$56.42M	$36.35M	-	-	-	-	-	-	-	-	-
Non-US	$74.53M	$81.98M	$117.96M	$96.50M	$115.10M	$55.70M	$76.60M	$77.00M	$79.20M	$69.70M	-
BRAZIL	-	$40.95M	-	-	-	-	-	-	-	-	-
United States	-	$36.35M	$343.96M	$65.70M	$54.60M	$58.20M	$54.80M	$56.80M	$48.60M	$47.50M	-
Non Us	-	-	-	-	-	-	-	-	-	-	$67.20M
U	-	-	-	-	-	-	-	-	-	-	$47.10M

PTC Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 25: Non-US (56.91%), and UNITED STATES (43.09%).

PTC Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
ALKS	Alkermes	$1.56B	$394.19M
ARWR	Arrowhead Pharmaceuticals	$829.45M	$542.71M
PTCT	PTC Therapeutics	$806.78M	$211.01M
KRYS	Krystal Biotech	$290.51M	$97.80M
ACLX	Arcellx	$107.94M	$7.55M
RNA	Avidity Biosciences	$10.90M	$12.47M
CRNX	Crinetics Pharmaceuticals	$1.04M	$143.00K
PTGX	Protagonist Therapeutics	-	-
TGTX	TG Therapeutics	-	$161.71M
PCVX	Vaxcyte	-	-
MTSR	Metsera	-	-

PTCT Revenue FAQ

What is PTC Therapeutics’s yearly revenue?

PTC Therapeutics's yearly revenue for 2024 was $806.78M, representing a decrease of -13.97% compared to 2023. The company's yearly revenue for 2023 was $937.82M, representing an increase of 34.20% compared to 2022. PTCT's yearly revenue for 2022 was $698.8M, representing an increase of 29.75% compared to 2021.

What is PTC Therapeutics’s quarterly revenue?

PTC Therapeutics's quarterly revenue for Q3 2025 was $211.01M, a 17.96% increase from the previous quarter (Q2 2025), and a 7.23% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $178.88M, a -84.79% decrease from the previous quarter (Q1 2025), and a -4.19% decrease year-over-year (Q2 2024). PTCT's quarterly revenue for Q1 2025 was $1.18B, a 451.71% increase from the previous quarter (Q4 2024), and a 459.73% increase year-over-year (Q1 2024).

What is PTC Therapeutics’s revenue growth rate?

PTC Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 15.45%, and for the last 5 years (2020-2024) was 111.88%.

What are PTC Therapeutics’s revenue streams?

PTC Therapeutics's revenue streams in c 24 are Collaboration Revenue, Product, Royalty, and Manufacturing. Collaboration Revenue generated $304K in revenue, accounting 0.04% of the company's total revenue, down -99.70% year-over-year. Product generated $600.95M in revenue, accounting 74.49% of the company's total revenue, up 106.30% year-over-year. Royalty generated $203.86M in revenue, accounting 25.27% of the company's total revenue Manufacturing generated $1.66M in revenue, accounting 0.21% of the company's total revenue, down -78.39% year-over-year.

What is PTC Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of PTC Therapeutics was Product. This segment made a revenue of $600.95M, representing 74.49% of the company's total revenue.